|
|
|
|
|
|
|
|
|
22.08.25 - 09:01
|
Employee representatives on the Board of Directors (Cision)
|
|
|
Unionen's local branch, UA Svea, has appointed Sara Lenasdotter and Lisa Öberg as employee representatives to the Board of Directors of Apotea AB (publ) (“Apotea”). The employee representatives will be members of the Board from 1 September 2025.
Sara Lenasdotter, born in 1992, is educated in packaging design at Brobygrafiska and has been working as a Designer at Apotea since 2021. Lisa Öberg, born in 1993, is educated as a graphic designer at Brobygrafiska and has been working as a Designer at Apotea since 2022.
Apotea's Board of Directors consists of the members elected by the Annual...
|
|
|
18.07.25 - 07:30
|
Apotea AB (publ) Interim report Q2 2025: Strengthened profitability and increased demand for prescription products (Cision)
|
|
|
Net revenue for the second quarter increased by 9.9% (26.1) to SEK 1,826.2 million (1,661.1) and operating profit (EBIT) excluding items affecting comparability amounted to SEK 99.3 million (78.6), corresponding to an adjusted EBIT margin of 5.4% (4.7%).
Second quarter (April 1 – June 30, 2025)
· Net revenue increased by 9.9% (26.1) to SEK 1,826.2 million (1,661.1)
· Gross margin was 28.0% (27.7)
· Operating profit (EBIT) amounted to SEK 93.1 million (75.3), corresponding to an EBIT margin of 5.1% (4.5)
· Operating profit (EBIT) excluding items affecting comparability amounted...
|
|
|
18.06.25 - 08:36
|
Invitation to Apotea′s Q2 2025 webcast (Cision)
|
|
|
Apotea AB (publ) (”Apotea”) will publish its Q2 2025 report at 07:30 am CEST on Friday the 18[th] of July. Investors, analysts, media and other interested parties are welcome to join a webcast and presentation of the interim report at 09:30 am the same day.
The results for the period January – June 2025 will be presented by Pär Svärdson, CEO and Johan Mårild, CFO via a webcast held on 18[th] of July 2025 at 09:30 am.
Link for webcast participation (no advance notification is necessary): https://apotea.events.inderes.com/q2-report-2025
If you wish to participate via teleconference,...
|
|
|
10.06.25 - 22:48
|
RESULTS OF PROPOSED PLACING OF SHARES IN APOTEA AB (PUBL) (Cision)
|
|
|
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY, NOR SHALL THERE BE ANY SALE OF THE SECURITIES REFERRED TO HEREIN, IN OR INTO ANY JURISDICTION WHERE SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.
PLEASE REFER TO THE...
|
|
|
10.06.25 - 17:36
|
PROPOSED PLACING OF SHARES IN APOTEA AB (PUBL) (Cision)
|
|
|
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY, NOR SHALL THERE BE ANY SALE OF THE SECURITIES REFERRED TO HEREIN, IN OR INTO ANY JURISDICTION WHERE SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.
PLEASE REFER TO THE...
|
|
|
28.05.25 - 11:48
|
Bulletin from Apotea AB′s (publ) Annual General Meeting on May 28, 2025 (Cision)
|
|
|
The Annual General Meeting (the “AGM”) of Apotea AB (publ), reg. no 556864-7324 (the “Company”) was held today, on 28 May 2025, whereupon the shareholders primarily resolved on the following matters with the required majority.
Adoption of the income statement and balance sheet
The AGM adopted the income statement and balance, as well as the consolidated income statement and consolidated balance sheet, for the financial year of 2024.
Dispositions regarding the Company's result
The AGM resolved, in accordance with the board of directors' proposal, that no dividend is to be paid for...
|
|
|
09.05.25 - 12:27
|
Apotea: "Schwedische Redcare" außer Rand und Band – die Hintergründe (Der Aktionaer)
|
|
|
Seit dem Dezember vergangenen Jahres ist der europäische Kurszettel um einen Online-Arzneimittelversender reicher. Die schwedische Apotea konnte an der Nasdaq in Stockholm ein furioses Listing feiern. Dass Anleger auf der Long-Seite bei dem Börsennewcomer voll auf ihre Kosten kommen, haben die jüngsten Zahlen gezeigt....
|
|
|
08.05.25 - 07:36
|
Apotea AB (publ) Interim report Q1 2025: Improved profitability and solid growth in times of uncertainty (Cision)
|
|
|
Net revenue for the first quarter increased by 15.2% to SEK 1,753.5 million (1,521.7) and operating profit (EBIT) amounted to SEK 92.4 million (62.2), corresponding to an EBIT margin of 5.3% (4.1%).
First quarter (January 1 – March 31, 2025)
· Net revenue increased by 15.2% to 1,753.5 SEKm (1,521.7)
· Gross margin was 27.7% (27.3)
· Operating profit (EBIT) amounted to 92.4 SEKm (62.2), corresponding to an EBIT margin of 5.3% (4.1)
· There were no items affecting comparability in the period (-)
· Operating profit (EBIT) excluding items affecting comparability amounted to 92.4...
|
|
|
29.04.25 - 07:30
|
Apotea publishes annual and sustainability report for the financial year 2024 (Cision)
|
|
|
Apotea AB's (publ) annual and sustainability report for the financial year 2024 is now available on the company's website: ir.apotea.se
The annual and sustainability report contains a summary of the past financial year and is available in both Swedish and English.
For further information, please contact:
Stefan Eriksson, deputy CEO & Investor Relations
E-mail: ir@apotea.se
This disclosure contains information that Apotea AB (publ) is obliged to make public pursuant to the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact...
|
|
|
23.04.25 - 09:36
|
Notice to Annual General Meeting in Apotea AB (publ) (Cision)
|
|
|
The Shareholders of Apotea AB (publ), reg. no 556864-7324 (the “Company”), are hereby summoned to the Annual General Meeting on Wednesday 28 May 2025 at 10.00 am at Nalen, Regeringsgatan 74, 111 38 Stockholm. Admission and registration will commence at 09.30 am.
Right to attend and notification
Shareholders who wish to attend the Annual General Meeting must:
· be entered in the share register maintained by Euroclear Sweden AB no later than Tuesday 20 May 2025; and
· notify the Company of their participation no later than Thursday 22 May 2025.
Notice shall be made according to...
|
|
|
11.04.25 - 13:01
|
The Nomination Committee′s proposal for the Board of Directors of Apotea AB (publ) (Cision)
|
|
|
Ahead of the annual general meeting of Apotea AB (publ) (“Apotea”) on May 28, 2025, the Nomination Committee hereby announces its proposal regarding the Chairman of the Board and other members of the Board.
The Nomination Committee proposes that Cecilia Qvist, Anders Eriksson, Joanna Hummel, Jonas Hagströmer, Monica Lindstedt, Per Schlingmann and Pär Svärdson are re-elected as members of the Board of Directors of Apotea. Furthermore, the Nomination Committee proposes re-election of Cecilia Qvist as Chairman of the Board. Maria Curman and Henrik Forsberg Schoultz have informed the Nomination...
|
|
|
04.04.25 - 08:36
|
Invitation to Apotea′s Q1 2025 webcast (Cision)
|
|
|
Apotea AB (publ) (”Apotea”) will publish its Q1 2025 report at 07:30 am CEST on Thursday the 8th of May. Investors, analysts, media and other interested parties are welcome to join a webcast and presentation of the interim report at 09:30 am the same day.
The results for the period January – March 2025 will be presented by Pär Svärdson, CEO, Sarah Ahnström, deputy CEO & COO, and Johan Mårild, CFO, via a webcast held on 8th of May 2025 at 09:30 am.
Link for webcast participation (no advance notification is necessary): https://apotea.events.inderes.com/q1-report-2025
If you wish to...
|
|
|
03.04.25 - 21:36
|
Apotea Sverige AB cooperates with the Swedish Competition Authority (Konkurrensverket) in an investigation on paid search advertising contacts (Cision)
|
|
|
Following the decision by the Swedish Competition Authority (Konkurrensverket) today, on April 3, 2025, in case no. 288/2022 regarding the cooperation between a number of Swedish digital healthcare providers on the advertising of digital healthcare services, Apotea announces the following:
The Swedish Competition Authority has launched an investigation on whether companies providing pharmacy services have been in contact regarding avoiding bidding on keywords corresponding to each other's brands in paid search advertising and whether such matters have been discussed in trade association...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
